Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452980 | 1.00 | BCHE (0.40) | BCHEMAOBMAOAADORA2AADORA1 | |
| SCHEMBL22555679 | 0.77 | OPRK1 (0.36) | ALOX5LMNASMN1; SMN2SIGMAR1 | |
| SCHEMBL21187251 | 0.77 | OPRK1 (0.36) | ALOX5LMNASMN1; SMN2SIGMAR1 | |
| SCHEMBL30514796 | 0.77 | OPRK1 (0.36) | ALOX5LMNASMN1; SMN2SIGMAR1 | |
| SCHEMBL21177130 | 0.73 | MEN1 (0.33) | ALOX5LMNASMN1; SMN2 | |
| SCHEMBL29452911 | 0.73 | MEN1 (0.33) | ALOX5LMNASMN1; SMN2 | |
| SCHEMBL21176973 | 0.73 | MEN1 (0.33) | ALOX5LMNASMN1; SMN2 | |
| SCHEMBL30514798 | 0.73 | MEN1 (0.33) | ALOX5LMNASMN1; SMN2 | |
| SCHEMBL25403938 | 0.70 | HDAC6 (0.63) | SIGMAR1 | |
| SCHEMBL21180314 | 0.70 | TAAR1 (0.38) | MAOBMAOASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| CN-108250058-B | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| CN-108250058-A | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2018-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | BCHE 2937/4885MAOB 1634/4885MAOA 2388/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | BCHE 2125/4885MAOB 1632/4885MAOA 1423/4885 |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | BCHE 2125/4885MAOB 1632/4885MAOA 1423/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | BCHE 2125/4885MAOB 1632/4885MAOA 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.